^
    Back
    Association details:
    Biomarker:ROS1 positive
    Cancer:Mesothelioma
    Drug:APG-2449 (ALK inhibitor, Multi-tyrosine kinase inhibitor, ROS1 inhibitor, FAK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    APG-2449 in Patients With Advanced Solid Tumors

    Excerpt:
    ...cohort two, ALK/ROS1 fusion gene positive without TKI treatment Patients with non-small cell lung cancer....
    Trial ID:
    NCT03917043
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1+ non–small cell lung cancer (NSCLC) or mesothelioma.

    Published date:
    05/26/2022
    Excerpt:
    ...APG-2449 in patients with second-generation TKI-resistant ALK/ROS1+ NSCLC or mesothelioma....Four partial responses (PRs) were observed in 14 ALK+ pts resistant to second-generation TKIs treated at the RP2D....In 10 TKI-naïve pts, the overall response rate was 80% (ALK+, 6/8; ROS1+, 2/2) and the disease control rate (DCR) was 100%.
    DOI:
    10.1200/JCO.2022.40.16_suppl.9071
    Trial ID:
    NCT03917043